CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-12 03:24:372018-10-15 03:25:04AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering
13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-08 03:21:032018-10-15 03:23:56AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference
03 Oct 2018 Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ solution, SmartAirLA will help patients with asthma and COPD […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-03 05:29:072018-10-05 05:29:30Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation
Clinical results demonstrate point-of-care regenerative medicine technology benefits in treatment of second- and third-degree burns using Spray-On Skin™ Cells Valencia, Calif., USA, and Melbourne, Australia, 27 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicinecompany, today announced that the results from two U.S. pivotalclinical trials demonstrating the effectiveness and clinical benefits of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-27 05:18:052018-10-05 05:28:44AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Interim results for the six months ended 30 June 2018 Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020 Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-26 05:13:262018-10-05 05:17:52Interim results for the six months ended 30 June 2018
Destiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-26 05:09:472018-10-05 05:10:33Destiny Pharma announces appointment of Chief Medical Officer
Valencia, Calif., USA, and Melbourne, Australia, 26 September 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-26 04:51:392018-10-05 05:08:15AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit
Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-24 01:11:542018-09-25 01:13:27AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
Point-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-20 04:11:372018-09-21 04:31:29AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the positive FDA feedback, AmpliPhi intends to seek […]
AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering
/in Armata PharmaceuticalsCATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]
AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference
/in Armata Pharmaceuticals13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]
Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation
/in Adherium03 Oct 2018 Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ solution, SmartAirLA will help patients with asthma and COPD […]
AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference
/in Avita MedicalClinical results demonstrate point-of-care regenerative medicine technology benefits in treatment of second- and third-degree burns using Spray-On Skin™ Cells Valencia, Calif., USA, and Melbourne, Australia, 27 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicinecompany, today announced that the results from two U.S. pivotalclinical trials demonstrating the effectiveness and clinical benefits of […]
Interim results for the six months ended 30 June 2018
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or the “Company”) Interim results for the six months ended 30 June 2018 Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020 Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]
Destiny Pharma announces appointment of Chief Medical Officer
/in Destiny PharmaDestiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]
AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 26 September 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D […]
AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
/in Armata PharmaceuticalsProfessor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]
AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
/in Avita MedicalPoint-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections
/in Armata PharmaceuticalsThe FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the positive FDA feedback, AmpliPhi intends to seek […]